Literature DB >> 11443520

RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia.

M S Sodhi1, P W Burnet, A J Makoff, R W Kerwin, P J Harrison.   

Abstract

5-HT(2C) receptor (5HT(2C)R, serotonin-2C) RNA undergoes editing to produce several receptor variants, some with pharmacological differences. This investigation comprised two parts: the characterisation of 5-HT(2C)R RNA editing in a larger human control sample than previously examined, and a comparative study in subjects with schizophrenia. Secondary structure analysis of the putative edited region of the human 5-HT(2C)R gene predicted the existence of a double stranded (ds) RNA loop, essential for RNA editing in this receptor. RNA was then extracted from frontal cortex of five controls and five subjects with schizophrenia. RT-PCR products of the edited region were cloned and sequenced (n = 100). Reduced RNA editing, increased expression of the unedited 5-HT(2C-INI) isoform in schizophrenia (P = 0.001) and decreased expression of the 5-HT(2C-VSV) and 5-HT(2C-VNV) isoforms were detected in the schizophrenia group. In addition, two novel mRNA edited variants were identified: 5-HT(2C-MNI) and 5-HT(2C-VDI). Screening of the 5-HT(2C)R gene did not reveal any mutations likely to disrupt the dsRNA loop, suggesting that the reduced RNA editing in schizophrenia may instead be caused by altered activity of the editing enzyme(s). Since the unedited 5-HT(2C-INI) is more efficiently coupled to G proteins than the other isoforms, its increased expression in schizophrenia may lead to enhanced 5-HT(2C)R-mediated effects. The results also illustrate that potentially important receptor alterations may occur in schizophrenia which are not detectable merely in terms of receptor abundance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443520     DOI: 10.1038/sj.mp.4000920

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  56 in total

Review 1.  RNA editing by adenosine deaminases that act on RNA.

Authors:  Brenda L Bass
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

2.  Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene.

Authors:  Rachel Flomen; Joanne Knight; Pak Sham; Robert Kerwin; Andrew Makoff
Journal:  Nucleic Acids Res       Date:  2004-04-15       Impact factor: 16.971

Review 3.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

Review 4.  A-to-I RNA editing and human disease.

Authors:  Stefan Maas; Yukio Kawahara; Kristen M Tamburro; Kazuko Nishikura
Journal:  RNA Biol       Date:  2006-01-12       Impact factor: 4.652

5.  Estimating RNA editing efficiency of five editing sites in the serotonin 2C receptor by pyrosequencing.

Authors:  Kazuya Iwamoto; Miki Bundo; Tadafumi Kato
Journal:  RNA       Date:  2005-10       Impact factor: 4.942

6.  Altered RNA editing in mice lacking ADAR2 autoregulation.

Authors:  Yi Feng; Christopher L Sansam; Minati Singh; Ronald B Emeson
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

Review 7.  Brain-specific small nucleolar RNAs.

Authors:  Boris Rogelj
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

8.  An accurate fluorescent assay for quantifying the extent of RNA editing.

Authors:  Loretta M Roberson; Joshua J C Rosenthal
Journal:  RNA       Date:  2006-09-06       Impact factor: 4.942

Review 9.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

10.  An ADAR that edits transcripts encoding ion channel subunits functions as a dimer.

Authors:  Angela Gallo; Liam P Keegan; Gillian M Ring; Mary A O'Connell
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.